Loading…
CervoMed Inc. disclosed 32-week data from the RewinD-LB trial extension phase.
CervoMed Inc. announced on 2025-07-28 CervoMed announced 32-week data from the RewinD-LB trial extension phase showing neflamapimod's sustained effect on slowing clinical progression in patients with Dementia with Lewy Bodies (DLB) and associated reduction in a key plasma biomarker of neurodegeneration, with results compared to Placebo.
The announcement cited 54% risk reduction, 64% risk reduction, 1.5-point increase in CDR-SB, -18.4±4.0 pg/mL, -21.2±4.4 pg/mL, +1.1±3.0 pg/mL, and +1.1±3.3 pg/mL.
CervoMed Inc. Common Stock has a free float of 5,423,100 shares and 9,252,700 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.